CrisprBits announces a strategic collaboration with Molbio Diagnostics to launch innovative CRISPR-based Point-of-Care tests
 |
The strategic partnership between CrisprBits and Molbio Diagnostics represents a significant milestone in the advancement of accessible, cost effective and accurate diagnostic testing in the frontline. The collaboration is set to identify and capitalize on market opportunities, bringing together their respective strengths and expertise. By harnessing the unprecedented sensitivity and specificity of RNA guide-based target identification of nucleic acid, and the presence of both cis and trans-cleavage property of certain Cas enzymes, CrisprBits has developed a platform to build rapid, precise, and affordable POC tests for a wide range of disease and health conditions. CrisprBits will spearhead the development of its platform, PathCrisp, for Point-of-Care testing. Simultaneously, Molbio Diagnostics will leverage its large-scale manufacturing capability and well-established sales and marketing network to promote and distribute the developed POC tests worldwide.
 |
| Crispr and Molbio MoU Ceremony |
"The reimagination of health systems in India has to ride on a central role played by “pervasive” diagnostic tests POCTs (Point-of-care tests) that are light on instruments, affordable and designed for ease of use by community health workers. This would enable better preventive care and early detection interventions in treatment. This innovation has to be driven in the LMICs (Low and Middle Income Countries) as developed economies have legacy infrastructure that addresses these issues with access to labs or clinics at a different scale. By teaming up with Molbio Diagnostics, we are combining our innovations in instrument-light CRISPR POCTs to develop and distribute a new generation of tests that are pervasive and will enable early detection and timely treatment," said Dr. Vijay Chandru, Chief Scientific Officer and Co-founder, CrisprBits
The collaboration will focus on building POCTs for swift and accurate detection of various pathogens and genetic markers at the site. The tests will be made available in diverse settings, including clinics, hospitals, and resource-limited areas, where access to reliable diagnostic tools is crucial.
Dr. Chandrashekar Nair, Chief Technical Officer of Molbio Diagnostics, expressed his enthusiasm for the partnership, stating, "We are very excited about this partnership with CrisprBits. The coming together of their innovation and Molbio’s strengths in translation, manufacturing and distribution has the potential to rapidly provide cutting edge diagnostics solutions where it is required the most. This collaboration aligns perfectly with our overarching mission to provide reliable and accessible point-of-care diagnostic solutions that empower healthcare professionals globally."
“CrisprBits was established with a clear mission to tackle crucial healthcare challenges by harnessing the groundbreaking potential of CRISPR technology. By partnering with Molbio diagnostics we strive to bring to these tests that impact real-time decision-making that leads to enhanced patient outcomes and more effective public health management,” Sunil Arora, Co-Founder and CEO, CrisprBits, said in a statement.
This strategic alliance aims to streamline the development, manufacturing, and distribution processes, ensuring the swift availability of these transformative POC tests to healthcare facilities and communities around the world.
About Molbio Diagnostics
Molbio Diagnostics is India’s first ‘unicorn’ in the medical technology sector that brings to healthcare professionals worldwide the Truelab® Real-Time Quantitative micro PCR system comprising Truenat® technology that makes Real-Time PCR testing possible in all laboratories, in the field and near-patient settings, thereby decentralizing and democratising access to molecular diagnostics. With a large and growing menu of Truenat® assays for infectious diseases, including TB, COVID-19, HIV, HCV, HBV, HPV, Influenza, etc., this rapid, portable and infrastructure agnostic technology enables early and accurate diagnosis and initiation of correct treatment right at the first point of contact. So far, this automated platform is deployed in over 6,000 PHC/CHCs in India and over 1500 testing centers in more than 40 countries around the world.
For more information, Please visit the website
https://www.molbiodiagnostics.com/
About CrisprBits
CrisprBits is one of the first Indian companies using CRISPR, a breakthrough gene-editing technology, to develop high-quality solutions in the life sciences that all Indians can afford. The company was founded by a team of entrepreneurs and scientists with vast experience in both the industry and academic sectors. They have a proven track record in developing diagnostics, precision medicine, and clinical-research solutions used by clinicians, pharmaceutical companies, and biotechnology firms globally, including in India.
CrisprBits operates under three key principles: using deep science to deliver high quality products; adhering to the highest ethical standards, including in the choice of products they offer; and developing an organization that draws exceptional individuals with diverse backgrounds and affinities.
With offices in Delhi and Bengaluru, their laboratory is located in C-CAMP, a premier incubator for biotechnology innovation in Bengaluru.
Website: https://crisprbits.com/
The collaboration will focus on building POCTs for swift and accurate detection of various pathogens and genetic markers at the site. The tests will be made available in diverse settings, including clinics, hospitals, and resource-limited areas, where access to reliable diagnostic tools is crucial.
Dr. Chandrashekar Nair, Chief Technical Officer of Molbio Diagnostics, expressed his enthusiasm for the partnership, stating, "We are very excited about this partnership with CrisprBits. The coming together of their innovation and Molbio’s strengths in translation, manufacturing and distribution has the potential to rapidly provide cutting edge diagnostics solutions where it is required the most. This collaboration aligns perfectly with our overarching mission to provide reliable and accessible point-of-care diagnostic solutions that empower healthcare professionals globally."
“CrisprBits was established with a clear mission to tackle crucial healthcare challenges by harnessing the groundbreaking potential of CRISPR technology. By partnering with Molbio diagnostics we strive to bring to these tests that impact real-time decision-making that leads to enhanced patient outcomes and more effective public health management,” Sunil Arora, Co-Founder and CEO, CrisprBits, said in a statement.
This strategic alliance aims to streamline the development, manufacturing, and distribution processes, ensuring the swift availability of these transformative POC tests to healthcare facilities and communities around the world.
About Molbio Diagnostics
Molbio Diagnostics is India’s first ‘unicorn’ in the medical technology sector that brings to healthcare professionals worldwide the Truelab® Real-Time Quantitative micro PCR system comprising Truenat® technology that makes Real-Time PCR testing possible in all laboratories, in the field and near-patient settings, thereby decentralizing and democratising access to molecular diagnostics. With a large and growing menu of Truenat® assays for infectious diseases, including TB, COVID-19, HIV, HCV, HBV, HPV, Influenza, etc., this rapid, portable and infrastructure agnostic technology enables early and accurate diagnosis and initiation of correct treatment right at the first point of contact. So far, this automated platform is deployed in over 6,000 PHC/CHCs in India and over 1500 testing centers in more than 40 countries around the world.
For more information, Please visit the website
https://www.molbiodiagnostics.com/
About CrisprBits
CrisprBits is one of the first Indian companies using CRISPR, a breakthrough gene-editing technology, to develop high-quality solutions in the life sciences that all Indians can afford. The company was founded by a team of entrepreneurs and scientists with vast experience in both the industry and academic sectors. They have a proven track record in developing diagnostics, precision medicine, and clinical-research solutions used by clinicians, pharmaceutical companies, and biotechnology firms globally, including in India.
CrisprBits operates under three key principles: using deep science to deliver high quality products; adhering to the highest ethical standards, including in the choice of products they offer; and developing an organization that draws exceptional individuals with diverse backgrounds and affinities.
With offices in Delhi and Bengaluru, their laboratory is located in C-CAMP, a premier incubator for biotechnology innovation in Bengaluru.
Website: https://crisprbits.com/
Advertisements